Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (120)	12/2/2004 11:32:36 AM
From: nigel bates	Respond to of 123

UCB to file CDP870 for rheumatoid arthritis in Dec 2006, Crohn's in Dec 2005 BRUSSELS (AFX) - Biopharmaceutical company UCB SA (Brussels: UCBBt.BR - news) said it is on target to file for regulatory approval its newly-acquired treatment for rheumatoid arthritis and Crohn's disease in Dec 2006 and Dec 2005 respectively. CDP870 was the most advanced molecule in the pipeline acquired in UCB's 2.25 bln eur takeover of British biotech firm Celltech PLC this summer. 'We are on target to file CDP870 for rheumatoid arthritis in December 2006,' said Melanie Lee, research and development director. She said the drug would be filed for Crohn's disease a year earlier, in December 2005. The market for rheumatoid arthritis is estimated to reach 9 bln eur by 2009, said UCB. The Crohn's disease market was worth 1 bln eur in 2004, with over 90 pct growth compared to 2003, the company said...